Mastering Biotech's Insourcing/Outsourcing Trade-Offs

By Andrew Knappenberger, Ph.D., Scientific Liaison & Project Manager, Somatek

Biotechnology companies face a recurring and consequential strategic question: Which activities should be performed internally, and which should be outsourced to external partners? While many frame this question as complex or context-dependent, the accumulated academic, professional, and industry evidence suggests a relatively stable set of governing principles. The challenge is less about discovering novel rules and more about consistently applying known tradeoffs under conditions of capital constraint, uncertainty, and timeline pressure.

At a high level, insourcing tends to be more expensive in the short term but offers superior control, knowledge retention, and strategic alignment. Outsourcing tends to reduce fixed costs and accelerate execution, but it introduces risks related to quality, coordination, delays, and the externalization of critical asset-specific learning. Most biotechs therefore operate best using a hybrid model: a small, highly capable internal core complemented by broad reliance on external vendors.

This paper argues that biotechs should insource what they cannot afford to lose and outsource what they cannot afford to build. Sponsors should keep core scientific judgment, early-stage research, and program leadership internal. They should outsource capital-intensive, episodic, or highly standardized activities — particularly Good Manufacturing Practices (GMP) production and many aspects of development. Importantly, effective outsourcing itself requires expertise. Companies that attempt to outsource without sufficient decision-making capability tend to underperform, while the episodic nature of such decisions makes insourcing this capability impractical.¹

The Strategic Nature Of Human Capital In Biotech

Biotechnology features long development timelines, high regulatory burdens, irreversible capital commitments, and extreme sensitivity to delays. Human capital decisions therefore carry outsized long-term consequences. A hiring decision made in preclinical development can affect burn rate, optionality, execution speed, and the probability of ultimate technical success.

Two structural features of biotech amplify the importance of these hiring decisions. First, much of a biotech company’s value resides in institutional knowledge: experimental judgment, interpretation of ambiguous data, and the integration of scientific, clinical, and regulatory considerations. Second, the sector relies heavily on infrastructure that no nascent company can reasonably internalize (e.g., clinical sites and manufacturing facilities).

As a result, the question is not whether to outsource, but how far teams can push outsourcing without eroding strategic control. Companies that internalize everything tend to fail financially; companies that externalize everything tend to fail operationally.

Insourcing vs. Outsourcing: Core Tradeoffs

Cost structure and capital efficiency

Insourcing converts variable costs into fixed costs. Hiring full‑time employees entails salary, benefits, equity, onboarding time, and long‑term commitment. In early‑stage biotechs with milestone‑based or venture‑backed financing, these commitments reduce flexibility and increase the risk of mismatch between workforce and company needs.²

Outsourcing, by contrast, preserves capital flexibility. Sponsors can engage CROs, CDMOs, and consultants when needed and disengage when programs pause or terminate. This option is particularly attractive given high attrition rates in drug development and the speed with which company priorities can change.

However, sponsors often overestimate apparent cost savings from outsourcing. They frequently fail to account for hidden costs, including rework, delays, contract renegotiations, and vendor switching, at the outset.³ Outsourcing reduces upfront spend but does not reliably reduce total program cost when projects are poorly governed.

Speed vs. agility

External vendors often outperform internal teams on speed for well‑defined tasks. Dedicated infrastructure, standardized processes, and accumulated experience allow CROs and CDMOs to execute faster than newly assembled internal teams. Integrated or “one‑stop shop” vendors further reduce handoff delays and coordination costs.^4,5

However, efficiency involves more than throughput under ideal conditions. The real test comes when data are ambiguous or unexpected. Internal teams can meet, interpret the signal, and pivot immediately. In contrast, outsourced programs must translate that same pivot into revised scopes, change orders, and vendor approvals, introducing delays at critical decision points.

Control, quality, and risk

Loss of control is a prominent and frequently cited risk of outsourcing. Sponsors commonly encounter quality failures, misaligned incentives, and schedule slippage. Academic literature shows that externally sourced activities face higher termination rates, particularly when internal expertise is weak.⁶

Crucially, outsourcing externalizes execution but not accountability.⁷ Regulators hold sponsors accountable for data integrity, compliance, and patient safety, regardless of who performed the work. Therefore, outsourcing without adequate internal oversight increases, rather than reduces, organizational risk.

Knowledge Spillover And The Case For Insourcing Early Research

Academic research on R&D outsourcing highlights a less intuitive but highly relevant factor: knowledge spillover. Early‑stage and transformative research generates knowledge that is broadly useful beyond a single asset. When companies outsource such work, they allow a significant portion of its value to leak to vendors and, indirectly, to competitors.⁸ This leakage occurs even without any bad-faith action on the part of the vendor or competitor.

From an economic perspective, high spillover reduces a firm’s willingness to pay for external research, because competitors benefit without bearing the cost. This creates a first‑mover disadvantage and biases firms toward incremental improvements, rather than transformative innovation, when outsourcing is prevalent.⁹

For biotechs, the implication is clear: sponsors should generally insource early-stage, platform-defining, or mechanistically novel research. Internal teams are better able to retain institutional knowledge and experimental intuition, protect strategic and proprietary insights, iterate rapidly without contractual friction, and align research direction tightly with long‑term strategy. However, outsourcing early research is defensible when the work is highly standardized or orthogonal to the company’s core differentiation.

Development And Manufacturing: The Case For Outsourcing

Manufacturing is structurally suited to outsourcing

Most biotechs should outsource manufacturing — full stop. The economics discourage internalization, since dedicated GMP facilities can easily have low utilization outside of narrow windows. They also require high and largely irreversible capital expenditures, face continuously evolving regulatory expectations, and must support increasingly complex and specialized modalities.¹⁰

Investors and boards generally view early manufacturing build-outs skeptically, often seeing idle facilities as inefficient capital use. CDMOs exist in part to spread these costs across multiple clients and programs.¹⁰

Development work and product specificity

Process development and analytical development occupy a middle ground. The guiding principle here is product specificity. Sponsors can often outsource work that is highly specific to one program and offers little strategic insight to competitors. Conversely, development capabilities that inform future programs or platform decisions may justify partial insourcing. Companies can reasonably retain internal process development leadership while outsourcing execution, and such leadership often proves instrumental during tech transfer activities.⁷

One‑stop shops vs. best‑of‑breed

Empirical evidence suggests that integrated vendors are faster but more expensive. In biotech, speed often outweighs cost. Delays erode patent life and increase financing risk. The financial impact of delays can easily exceed moderate increases in spending, reaching millions or tens of millions of dollars.^4,5 As a result, biotechs, especially those in their early stages, tend to benefit from integrated vendors despite the higher nominal pricing.²

The Seven Deadly Sins Of Outsourcing

Empirical analysis of failed outsourcing efforts identifies seven recurring failure modes that are highly relevant to biotech.³

1. Outsourcing activities that should not be outsourced
2. Selecting vendors based primarily on price
3. Poorly specified contracts that fail to anticipate change
4. Neglect of personnel continuity and institutional knowledge
5. Loss of operational control
6. Underestimation of hidden costs and delays
7. Failure to plan for an exit from the outsourcing relationship

Biotech amplifies these risks due to regulatory scrutiny, long timelines, and finite patent life. Thus, vendor selection and contract design are among the most impactful decisions a management team makes.

The Need For Specialized Vendor Selection Expertise

Industry experience strongly suggests that companies should invest in specialized expertise to guide vendor selection.^2,10 Startups often lack the internal bandwidth or pattern recognition required to design and run maximally effective requests for proposals (RFPs) for CRO or CDMO engagements, yet mistakes made at this stage are among the most expensive and difficult to unwind.

When companies outsource without sufficient experience and decision-making capability, they often default to blind trust in vendors.² Small companies are particularly vulnerable and often accept narratives of versatility at face value.

Sponsors often frame vendor selection as a purely technical exercise, but procedural and transactional constraints heavily shape it in practice. Given the financial impact of delays, selecting a vendor on lowest bid alone is frequently a false economy. At the same time, vendors tend to provide pricing and other key information late in the process. Sponsors must secure confidentiality agreements and invest significant administrative effort to obtain and interpret this information. For small biotechs, this burden can skew decisions toward what is easiest to evaluate, rather than what matters most.¹¹

Specialists who focus on CRO and CDMO sourcing can manage both the technical assessment and the transactional complexity of this process. By doing so, they reduce the likelihood that incomplete information, time pressure, or procedural friction will ultimately drive the vendor selection outcome.¹⁰

Practical Heuristics For Decision‑Makers

While every program is unique, several heuristics consistently provide sound guidance. Companies cannot afford to insource everything or outsource everything. Sponsors should insource when vendors require significant training or when knowledge spillover is high, and outsource when capital intensity is high and utilization is low. Speed often matters more than nominal cost. Specialized expertise is a prerequisite for successful outsourcing. Vendor quality matters more than vendor pricing.

These rules sound simple yet remain difficult to follow. They require discipline, restraint, and a willingness to invest in invisible capabilities. They also require sponsors to stay the course despite emotional and organizational pressure, making them psychological as well as intellectual challenges.

Conclusion

Human capital decisions in biotech determine where scientific judgment, financial exposure, and execution risk ultimately reside as programs advance through uncertainty. Most companies benefit from a deliberately hybrid model.

By insourcing core judgment and strategy while outsourcing execution‑heavy, capital‑intensive activities, biotechs can preserve flexibility without sacrificing control. The failure modes are well documented, and the lessons are widely available. The remaining challenge is execution.

Ultimately, successful companies are not those that outsource the most, but those that outsource scrupulously, with clarity about what must remain internal, what they should delegate, and when they should bring in the right external expertise to inform high-stakes decisions.

References:

1. K. Getz, "Hard Truths about Executing Outsourcing Relationships," Pharmaceutical Outsourcing, 21 July 2016.
2. M. Shapiro, Interviewee, Clinical Outsourcing & Insourcing: Selecting the Right Model or Mix with Mark Shapiro. [Interview]. 2025.
3. J. Barthelemy, "The seven deadly sins of outsourcing," Academy of Management Perspectives, vol. 17.2, pp. 87-98, 2003.
4. J. DiMasi, "Assessing the financial benefits of faster development times: the case of single-source versus multi-vendor outsourced biopharmaceutical manufacturing," Clinical Therapeutics, vol. 40.6, pp. 963-972, 2018.
5. J. DiMasi, "The Net Financial Benefits of Single Vendor Integrated CDMO and CRO Drug Development Services," Research Square, 2025.
6. L. Purdy, "Technology sourcing and the dark side of open innovation: Evidence from the biopharmaceutical sector," Technovation, vol. 119, p. 102521, 2023.
7. S. Haigney, "Contracting Out Frees Sponsors Up," 4 August 2024. [Online]. Available: https://www.biopharminternational.com/view/contracting-out-frees-sponsors-up. [Accessed 3 February 2026].
8. E. B. de Villemeur, "Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?," Drug Discovery Today, p. 103333, 2022.
9. S. Gu, "Production Outsourcing and Innovation: Evidence from China’s Pharmaceutical Industry," SSRN, p. 4770849, 2024.
10. Carter, "In Search of a CMO for My Biotechnology Startup," BioProcess International, pp. 1-2, 2022.
11. G. Playter, "The Outsourcing Success Story," 3 June 2023. [Online]. Available: https://www.pharmtech.com/view/the-outsourcing-success-story. [Accessed 3 February 2026].

About The Author:

Andrew Knappenberger works at the interface of science and project management, supporting protein biologics and viral vector process development. He holds a Ph.D. in biochemistry from Case Western Reserve University and brings hands-on experience in protein engineering, molecular biology, and chromatography, helping teams execute effectively as both a scientist and a manager. Contact him at aknappenberger@somatek.com